The Correlation Between TNF-α Promoter Gene Polymorphism and Genetic Susceptibility to Cervical Cancer

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2018 Jun 27

PMID 29940817

Citations 6

Authors

Xiuyun Li

Geping Yin

Juan Li

Aifang Wu

Zheng Yuan

Jing Liang

Qinghua Sun

Affiliations

Soon will be listed here.

Abstract

To investigate the association between the susceptibility to cervical cancer and the single nucleotide polymorphisms of 5 tumor necrosis factor-α promoter genes (rs361525, rs1800629, rs1800750, rs1799964, and rs673) in Chinese women. A total of 946 peripheral blood samples were collected from women of Han Ethnicity in Shandong province. Of them, 452 were diagnosed with cervical squamous cell carcinomas. The study also included a control group of 494 healthy women. The targeted single nucleotide polymorphisms were analyzed by TaqMan probe method. (1) The rate of high-risk subtype human papillomavirus infection in exfoliated cervical epithelial cells was significantly higher in patients with cervical cancer than the control group (91.4% vs 10.3%, P < .01). The rate of human papillomavirus infection was lower in patients with carcinoma in situ than those with invasive carcinoma (77.9% vs 95.4%, P < .01). (2) There was a significant difference for rs361525 genotype (CC/CT/TT) between the control, carcinoma in situ, and invasive carcinoma groups ( P < .001). Both rs1800629 and rs1799964 genotypes (both GG/GA/AA) were also different between these groups ( P < .001 and P < .001). (3) The allele frequencies of rs361525, rs1800629, and rs1799964 were significantly correlated with the diagnosis of cervical cancer. The frequency of T allele in rs361525 was significantly higher for cervical cancer group (10.8%) than control group (3.8%; odds ratio = 3.04, 95% confidence interval = 1.76-5.25, P < .01). The frequency of A allele in rs1800629 was significantly higher for cervical cancer (29.9%) than control group (14.2%; odds ratio = 2.58, 95% confidence interval = 1.87-3.56, P < .01). The frequency of A allele in rs1799964 was also higher for cervical cancer group (38.3%) than control group (16.4%; odds ratio = 1.43, 95% confidence interval = 1.07-1.91, P < .05). The rs361525, rs1800629, and rs17999645 were significantly correlated with the diagnosis of cervical cancer.

Citing Articles

A Comprehensive Integration of Data Regarding the Correlation of TNF-α rs1800629 Polymorphism with Susceptibility to Cervical Cancer.

Marzbanrad Z, Karimi-Zarchi M, Noei-Teymoordash S, Motamedinasab M, Azizi S, Noori-Ardebili S Asian Pac J Cancer Prev. 2024; 25(4):1155-1167.

PMID: 38679974 PMC: 11162705. DOI: 10.31557/APJCP.2024.25.4.1155.

Single Nucleotide Polymorphisms of , , , and Genes and Susceptibility to Cervical Cancer in the Northern Chinese Han Population.

Feng Y, Wang Z, Zhu M, Li S, Dong S, Gong L Front Oncol. 2022; 12:878529.

PMID: 35814404 PMC: 9267950. DOI: 10.3389/fonc.2022.878529.

Genetic Association between TNFA Polymorphisms (rs1799964 and rs361525) and Susceptibility to Cancer in Systemic Sclerosis.

Kosalka-Wegiel J, Licholai S, Dziedzina S, Milewski M, Kuszmiersz P, Rams A Life (Basel). 2022; 12(5).

PMID: 35629365 PMC: 9145848. DOI: 10.3390/life12050698.

The Association of Promoter Polymorphisms with Genetic Susceptibility to Cervical Cancer in a Chinese Han Population.

Yang J, Wang Y, Zhang S, Li Y, Li C, Liu W Int J Gen Med. 2022; 15:417-427.

PMID: 35046703 PMC: 8760922. DOI: 10.2147/IJGM.S350263.

Clinical Effects of Chinese Herbal Decoction Combined with Basic Chemoradiotherapy and Nursing Intervention in the Treatment of Cervical Cancer and the Effect on Serum CEA, CA125, and TNF- Levels.

Gao L, Lv J, Hou L, Yuan Y, Wan Q Evid Based Complement Alternat Med. 2021; 2021:1446864.

PMID: 34603461 PMC: 8483916. DOI: 10.1155/2021/1446864.

References

Azmy I, Balasubramanian S, Wilson A, Stephenson T, Cox A, Brown N . Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res. 2004; 6(4):R395-400. PMC: 468647. DOI: 10.1186/bcr802. View

Liu L, Yang X, Chen X, Kan T, Shen Y, Chen Z . Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2011; 39(3):2683-8. DOI: 10.1007/s11033-011-1022-9. View

Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A . G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun. 2005; 334(2):588-92. DOI: 10.1016/j.bbrc.2005.06.137. View

Madeleine M, Anttila T, Schwartz S, Saikku P, Leinonen M, Carter J . Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer. 2006; 120(3):650-5. PMC: 4049152. DOI: 10.1002/ijc.22325. View

Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A . Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010; 126(3):763-70. DOI: 10.1007/s10549-010-1184-5. View

Li J, Kang L, Qiao Y . Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev. 2011; 12(5):1149-53. View

Badano I, Stietz S, Schurr T, Picconi A, Fekete D, Quintero I . Analysis of TNFα promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2011; 53(1):54-9. DOI: 10.1016/j.jcv.2011.09.030. View

Mehta A, Jordanova E, van Wezel T, Uh H, Corver W, Kwappenberg K . Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer. 2007; 46(6):577-86. DOI: 10.1002/gcc.20441. View

Madeleine M, Johnson L, Smith A, Hansen J, Nisperos B, Li S . Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 2008; 68(9):3532-9. PMC: 2662593. DOI: 10.1158/0008-5472.CAN-07-6471. View

10.

Yang Y, Luo C, Feng R, Bi S . The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2010; 137(6):947-52. DOI: 10.1007/s00432-010-0959-8. View

11.

Carrington M, Wang S, Martin M, Gao X, Schiffman M, Cheng J . Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005; 201(7):1069-75. PMC: 2213116. DOI: 10.1084/jem.20042158. View

12.

Fong C, Siddiqui A, Mark D . Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994; 22(6):1108-14. PMC: 307937. DOI: 10.1093/nar/22.6.1108. View

13.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

14.

Sachidanandam R, Weissman D, Schmidt S, Kakol J, Stein L, Marth G . A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409(6822):928-33. DOI: 10.1038/35057149. View

15.

Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11):796-802. DOI: 10.1093/jnci/87.11.796. View

16.

Danforth K, Rodriguez C, Hayes R, Sakoda L, Huang W, Yu K . TNF polymorphisms and prostate cancer risk. Prostate. 2008; 68(4):400-7. DOI: 10.1002/pros.20694. View

17.

Yin G, Zhu T, Li J, Wu A, Liang J, Zhi Y . CXCL12 rs266085 and TNF-α rs1799724 polymorphisms and susceptibility to cervical cancer in a Chinese population. Int J Clin Exp Pathol. 2015; 8(5):5768-74. PMC: 4503166. View

18.

Govan V, Constant D, Hoffman M, Williamson A . The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006; 6:24. PMC: 1397852. DOI: 10.1186/1471-2407-6-24. View

19.

McDougall J . Cofactors in the progression of HPV-associated tumors. Antibiot Chemother (1971). 1994; 46:150-64. DOI: 10.1159/000423642. View

20.

Deshpande A, Nolan J, White P, Valdez Y, Hunt W, Peyton C . TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005; 191(6):969-76. DOI: 10.1086/427826. View